Effect of Atorvastatin on Pancreatic Beta-Cell Function and Insulin Resistance in Type 2 Diabetes Mellitus Patients: A Randomized Pilot Study

被引:13
作者
Goyal, Aman [1 ]
Singh, Surender [1 ]
Tandon, Nikhil [2 ]
Gupta, Nandita [2 ]
Gupta, Yogendra Kumar [1 ]
机构
[1] All India Inst Med Sci, Dept Pharmacol, New Delhi 110029, India
[2] All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi 110029, India
关键词
atorvastatin; beta-cell function; dyslipidemia; insulin resistance; type 2 diabetes mellitus; DOUBLE-BLIND; CHOLESTEROL; SIMVASTATIN; SECRETION; STATINS; SENSITIVITY; INHIBITION; ABCA1; HYPERCHOLESTEROLEMIA; HOMEOSTASIS;
D O I
10.1016/j.jcjd.2014.01.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Statins are commonly used for the management of dyslipidemia in type 2 diabetes mellitus patients. We hypothesized that atorvastatin could modulate the beta-cell function by altering the levels of proapoptotic and antiapoptotic lipoproteins and could also have an effect on insulin resistance. The aim of the present pilot study was to assess the effect of atorvastatin 10 mg on pancreatic beta-cell function and insulin resistance in patients with hyperlipidemia and type 2 diabetes by using the homeostasis model assessment-2 (HOMA2) index. Methods: Fifty-one type 2 diabetes patients receiving oral antidiabetes drugs, not taking statins, with baseline low-density lipoprotein cholesterol between 2.6 mmol/L and 4.1 mmol/L were included. Forty-three patients (21 in placebo group and 22 in atorvastatin group) completed the study and were taken up for final analysis. Fasting blood samples were obtained at baseline and at 12 weeks to determine levels of blood glucose, lipid profile, insulin, C-peptide and glycosylated hemoglobin (A1C). Results: Atorvastatin nonsignificantly increased fasting serum insulin (+14.29%, p=0.18), accompanied by marginal nonsignificant increases in fasting plasma glucose and A1C. There was a decrease in HOMA2 percent beta-cell function (-2.9%, p=0.72) and increase in HOMA2 insulin resistance (+14%, p=0.16) in the atorvastatin group as compared with baseline, but the difference was not statistically significant. Conclusions: Atorvastatin in the dose used failed to produce significant change in pancreatic beta-cell function and insulin resistance in type 2 diabetes patients as assessed by the HOMA2 index. The possible explanations include absence of lipotoxicity at prevailing levels of dyslipidemia at baseline or inadequacy of statin dose used in the study. (Clinical Trials Registry-India:CTRI/2008/091/000099) (C) 2014 Canadian Diabetes Association
引用
收藏
页码:466 / 472
页数:7
相关论文
共 37 条
[1]   Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis [J].
Baker, William L. ;
Talati, Ripple ;
White, C. Michael ;
Coleman, Craig I. .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 87 (01) :98-107
[2]   Free fatty acids in obesity and type 2 diabetes:: defining their role in the development of insulin resistance and β-cell dysfunction [J].
Boden, G ;
Shulman, GI .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2002, 32 :14-23
[3]   The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL [J].
Bradley, C ;
Todd, C ;
Gorton, T ;
Symonds, E ;
Martin, A ;
Plowright, R .
QUALITY OF LIFE RESEARCH, 1999, 8 (1-2) :79-91
[4]   β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment [J].
Brunham, Liam R. ;
Kruit, Janine K. ;
Pape, Terry D. ;
Timmins, Jenelle M. ;
Reuwer, Anne Q. ;
Vasanji, Zainisha ;
Marsh, Brad J. ;
Rodrigues, Brian ;
Johnson, James D. ;
Parks, John S. ;
Verchere, C. Bruce ;
Hayden, Michael R. .
NATURE MEDICINE, 2007, 13 (03) :340-347
[5]   Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes [J].
Chamberlain, LH .
FEBS LETTERS, 2001, 507 (03) :357-361
[6]   Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes [J].
Chu, C-H. ;
Lee, J-K. ;
Lam, H-C. ;
Lu, C-C. ;
Sun, C-C. ;
Wang, M-C. ;
Chuang, M. J. ;
Wei, M-C. .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2008, 31 (01) :42-47
[7]   Simvastatin induces activation of the serine-threonine-protein kinase Akt and increases survival of isolated human pancreatic islets [J].
Contreras, JL ;
Smyth, CA ;
Bilbao, G ;
Young, CJ ;
Thompson, JA ;
Eckhoff, DE .
TRANSPLANTATION, 2002, 74 (08) :1063-1069
[8]   High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus [J].
Drew, Brian G. ;
Duffy, Stephen J. ;
Formosa, Melissa F. ;
Natoli, Alaina K. ;
Henstridge, Darren C. ;
Penfold, Sally A. ;
Thomas, Walter G. ;
Mukhamedova, Nigora ;
de Courten, Barbora ;
Forbes, Josephine M. ;
Yap, Felicia Y. ;
Kaye, David M. ;
van Hall, Gerrit ;
Febbraio, Mark A. ;
Kemp, Bruce E. ;
Sviridov, Dmitri ;
Steinberg, Gregory R. ;
Kingwell, Bronwyn A. .
CIRCULATION, 2009, 119 (15) :2103-U134
[9]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[10]   Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients [J].
Gannagé-Yared, MH ;
Azar, RR ;
Amm-Azar, M ;
Khalifé, S ;
Germanos-Haddad, M ;
Neemtallah, R ;
Halaby, G .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (07) :947-951